S-3758-119
Committee on Veterans' Affairs. Ordered to be reported with an amendment in the nature of a substitute favorably.
Sponsored by Jeanne Shaheen (D-NH)
What it does
This bill would require the Department of Veterans Affairs (VA) to provide opioid overdose rescue medications — such as naloxone — at no cost and without a prescription to eligible veterans and their registered caregivers at VA pharmacies. It would also require the VA to provide drug-use information alongside the medication, restrict how any personal data collected during distribution can be used, and mandate annual reports to Congress on program usage and potential expansion.
Who benefits
Eligible veterans who use VA health care, particularly those at risk of opioid overdose or who live with others who use opioids. Registered family caregivers of veterans who would gain direct access to the medication. Households of veterans where a family member's overdose risk is present. First responders and bystanders who may benefit indirectly from wider naloxone availability in veteran communities. Veterans who might otherwise avoid seeking naloxone due to cost, prescription barriers, or fear that the request would be used against them in employment or legal contexts.
Who is hurt
VA pharmacy budgets would absorb the cost of providing medications at no charge, potentially competing with other VA health care spending priorities. Private pharmacies and retail naloxone distributors may lose some business from veterans who would otherwise purchase naloxone commercially. Non-VA community health providers who serve veterans may face indirect competitive pressure. Veterans not enrolled in VA health care (and thus not "covered veterans") would not benefit, potentially widening the gap between enrolled and unenrolled veterans.
Supporters argue
Supporters argue that veterans die from opioid overdoses at roughly twice the rate of the general population, and that cost and prescription barriers are documented obstacles to naloxone access. They contend that removing both barriers simultaneously — cost and the prescription requirement — directly addresses the two most commonly cited reasons people do not obtain the medication. The bill's data-use restrictions are designed to eliminate a specific deterrent: fear that seeking naloxone will be recorded as evidence of drug use or used to deny employment, which research suggests discourages at-risk individuals from seeking help.
Opponents argue
Opponents argue that distributing naloxone without a prescription and without clinical oversight may reduce the incentive for veterans to engage with addiction treatment programs, potentially enabling continued opioid use rather than addressing its root causes. They contend that the VA already has existing naloxone distribution programs and that mandating no-cost, no-prescription access adds administrative and fiscal obligations without clear evidence that the marginal expansion will meaningfully reduce overdose deaths beyond current efforts. Critics may also raise concerns that the data-use restrictions, while well-intentioned, could complicate VA's ability to coordinate care and identify veterans who need broader substance use treatment.